Please assess the completion status of the following clinical trial:

Trial Title: Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
MAIN ELIGIBILITY CRITERIA~* Histologically proven metastatic adenocarcinoma of colon or rectum~* Documented inoperable disease (i.e., not suitable for complete carcinological surgical resection)~* Measurable lesion as assessed by CT scan or MRI in at least one dimension (longest diameter to be recorded) ≥ 20 mm with conventional CT scan or ≥ 10 mm with spiral CT scan~* No previous therapy for metastatic disease~* No history or evidence upon physical examination of CNS disease (e.g., non-irradiated CNS metastasis, seizure not controlled with standard medical therapy, or history of stroke) unless adequately treated~* No exclusive bone metastasis~* ECOG performance status 0-2~* WBC ≥ 1,500/mm\^3~* Platelets ≥ 100,000/mm\^3~* Hemoglobin \> 9 g/dL (may be transfused to maintain or exceed this level)~* Proteinuria \< 2+ by dipstick OR ≤ 1 g of protein on 24-hr urine collection~* Bilirubin \< 1.5 times ULN~* Alkaline phosphatase \< 3 times ULN~* No peripheral sensory neuropathy~* Negative pregnancy test~* Fertile patients must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly, or surgically sterilization)~* No peripheral neuropathy ≥ grade 1~* No clinically significant (i.e. active) cardiovascular disease~* No evidence of bleeding diathesis or coagulopathy~* No serious, non-healing wound, ulcer, or bone fracture~* No significant ophthalmologic abnormality~* More than 28 days since prior major surgical procedure or open biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- bevacizumab alone (Type: ACTIVE_COMPARATOR): None
- Bevacizumab + erlotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).